Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGL101 in ALSP (Ignite Study)
NCT05677659Phase 2Terminated
- Sponsor
- Vigil Neuroscience
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of iluzanebart in leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), sponsored by Vigil Neuroscience. Started Dec 2022; status: terminated.
02
Drugs
iluzanebart
03
Conditions
leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)
Beyond the preview
Go deeper on NCT05677659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677659.